

PSEUDOMYXOMASURVIVOR

England & Wales · Charity number 1143642

Details

Other names ONE IN A MILLION

Status Registered

Legal form Other

Registered 2011-09-02

Register [View on the Charity Commission register](#)

Contact

Address Appletree House
Mill Lane
Ellerton
York
YO42 4PA

Phone 03003020050

Email hello@pseudomyxomasurvivor.org

Website <https://www.pseudomyxomasurvivor.org>

Activities

Objects: 1) THE RELIEF OF SICKNESS AND MENTAL AND EMOTIONAL DISTRESS OF THOSE SUFFERING FROM PSEUDOMYXOMA, THEIR FAMILIES AND CARERS, IN PARTICULAR BY THE PROVISION OF A WEBSITE PROVIDING ADVICE, INFORMATION AND SUPPORT, AND 2) TO PROVIDE FUNDS TO SUPPORT RESEARCH INTO PSEUDOMYXOMA, ITS CAUSES, TREATMENT AND CURE AND PUBLISH THE USEFUL RESULTS OF SUCH RESEARCH.

Activities: RAISES AWARENESS OF A RARE CANCER TYPE, PSEUDOMYXOMA PERITONEI, WHICH AFFECTS AROUND THREE OR FOUR PEOPLE PER MILLION EACH YEAR WORLDWIDE. AWARENESS IS RAISED THROUGH LOCAL, NATIONAL AND INTERNATIONAL CAMPAIGNS, THROUGH THE PROVISION OF A WEBSITE AND THROUGH LEAFLETS. WE AIM TO RAISE FUNDS TO HELP RELIEVE THE EMOTIONAL AND MENTAL STRESS OF THIS RARE DIAGNOSIS AND TO RAISE FUNDS INTO RESEARCH.

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Advocacy/advice/information
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies, Other Defined Groups

Geography

- Throughout England And Wales

Finances

| Period end | Income | Expenditure | Assets | Employees |
|------------|----------|-------------|--------|-----------|
| 2025-08-31 | £124,369 | £82,431 | - | - |
| 2024-08-31 | £64,216 | £77,257 | - | - |
| 2023-08-31 | £87,687 | £106,442 | - | - |
| 2022-08-31 | £67,193 | £32,054 | - | - |
| 2021-08-31 | £73,197 | £21,569 | - | - |

Trustees

| Name | Role | Appointed |
|--------------------------|-------|------------|
| Susan Oliver | Chair | 2015-01-28 |
| Anne Charlotte Salisbury | | 2019-05-10 |
| Clare Fletcher | | 2021-04-30 |
| Madeleine Claire Lomas | | 2025-06-23 |
| Timothy Brill | | 2023-01-01 |

PSEUDOMYXOMASURVIVOR

England & Wales - Charity number 1143642

Accounts

REGISTERED CHARITY NUMBER: 1143642


**Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 August 2025
for
Pseudomyxoma Survivor**

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Pseudomyxoma Survivor

**Contents of the Financial Statements
for the Year Ended 31 August 2025**

| | Page |
|--|-------------|
| Report of the Trustees | 1 to 6 |
| Independent Examiner's Report | 7 |
| Statement of Financial Activities | 8 |
| Balance Sheet | 9 |
| Notes to the Financial Statements | 10 to 16 |



PSEUDOMYXOMA SURVIVOR - ANNUAL REPORT TO 31 AUGUST 2025

The trustees present their report with the financial statements of the charity for the year ended 31 August 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OUR OBJECTIVES, AIMS AND ACTIVITIES:

Pseudomyxoma Survivor's main objectives (as set out in the Constitution) are:

- To relieve the sickness, mental and emotional distress of those suffering from pseudomyxoma peritonei (PMP), their families and carers.
- To provide funds to support research into pseudomyxoma peritonei, its causes, treatment and cure and to publish the useful results of such research.
- To promote awareness of pseudomyxoma peritonei.

Notice of bereavement:

It is with deep sorrow that we announced the passing of our esteemed Trustee, **Angela Brook** in April 2025. Angela devoted more than twelve years to the leadership and development of **Pseudomyxoma Survivor**, and we were privileged to benefit from her unwavering commitment and service.

As a patient living with pseudomyxoma peritonei, Angela dedicated her time and expertise to advancing the charity's mission. She played a pivotal role in building and maintaining our website, as well as establishing robust governance systems and procedures essential to the effective management of the charity. Angela's compassion and insight touched countless patients and their families. She provided invaluable support to patients and caregivers, guiding them through unfamiliar and challenging circumstances with empathy and understanding. Her legacy is one of friendship, resilience, and profound dedication to the community she served.

OUR ACHIEVEMENT AND PERFORMANCE:

In order to **support our patients and their caregivers** we have provided:

- A website providing focussed advice, information and support.
- A private Facebook group, which has over 1400 members from across the world. Patients are based in predominantly English-speaking countries with members worldwide.
- Practical as well as emotional support to patients and families through our grant programme and have given financial support to 16 families this year (3 applications were declined). A total of £14,500 was paid.
- The ongoing provision of a Buddy Scheme to provide one-to-one support to patients and caregivers around the world.
- Access to a family flat in Manchester, to support the families of those patients being treated at The Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains personalised blankets and information about Pseudomyxoma Survivor. Funding was provided in previous years and will be done so again as required.
- Ward toiletries to The Christie and Basingstoke.
- Support to patient days at both the Christie and Basingstoke hospitals

In order to **promote awareness of pseudomyxoma peritonei**, Trustees have:

- Attended the 14th International Congress on Peritoneal Surface Malignancies in Lyon, France. The conference was a joint meeting of the Peritoneal Surface Oncology Group International (PSOGI) and the International Society for the Study of Pleura and Peritoneum (ISSPP) and dedicated to improving the treatment and survival of peritoneal metastases.
- Attended various sessions hosted by National Voices, Findacure and data studies
- Attended Cancer52 meetings
- Promoted Rare Disease Day (28th February 2025)
- Published weekly posts on all social media channels regarding the disease
- Supported many competitors and volunteers, by providing merchandise for a wide variety of events
- Provided specialist leaflets for the hospitals to hand out to patients.

We have contributed funds to the following **research programmes** during the year to 31 August 2025:

- The team at the Peritoneal Malignancy Institute at Basingstoke & North Hampshire Hospitals NHS Foundation Trust are undertaking a research programme to analyse patient data to craft a machine learning predictive model for recurrence and survival, to guide clinical decisions and treatment plans.
- We are continuing to monitor the Norwegian GNAS Vaccine Trial at Oslo University [Oslo University GNAS research programme](#). We are delighted to confirm this has now been approved for human patient trials and the first patient has received their vaccine.

We continue to provide pro-bono support of research trials and studies:

- Assistance with an application towards a dietary study in Australia etc.

Pseudomyxoma Survivor's purpose and its activities contribute to the public benefit through activities to support these objectives. We are here to help patients understand the treatment options, provide leaflets and online resources that they can trust. We represent the PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness of the disease.

We take pride in the stewardship of our donations, which we demonstrated through this year with our committed registration with the Fundraising Regulator. Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities.

Charitable activities:

Pseudomyxoma is entirely reliant upon donations for our income and due to our very generous supporters, we have received £124,369 in donations and other income.

We are indebted to all of our fundraisers and their families and friends for their generosity.

Our Facebook support group goes from strength to strength, and we have continued support for the pseudomyxoma peritonei community on RareConnect, a Eurordis initiative that provides a multi-lingual support platform for rare diseases and on the platform operated by Cancer Research.

We have continued to develop a close working relationship with the teams at the Basingstoke and North Hampshire Hospital and The Christie Hospital in Manchester, which allows us to better support patients, and identify research opportunities.

Once again we were able to retain our status with the Great Non Profits organisation.

FINANCIAL REVIEW

Financial position:

We are extremely pleased that we have total funds of £257,787 at the end of the financial year. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

Pseudomyxoma Survivor's income and expenditure is relatively small and consequently the charity does not have sufficient funds to invest in longer term investments such as stocks and shares.

Reserves policy:

Through prudence in our activities, we are now able to ensure that we have a reserve in future years. We will do this through our plan which ensures the charity has reserves to cover our patient grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward, for 24 months. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

During the year to 31 August 2025, 12 months' expenditure equated to £31,931, plus the expenditure on research of £36,000 and family grants of £14,500, totalling £82,431. Whereas reserves at the period end totalled £257,787 and reserves excluding designated funds totalled £121,287.

We have designated expenditure as at the year ended 31 August 2025 of £136,500 (2024: £79,098) which will be spent in accordance with our charitable objectives, aims and activities which are detailed in the Trustee Report. All opportunities will be scrutinised in accordance with our due diligence procedures before any expenditure is committed.

Future plans:

With very grateful thanks to our very generous donors, we have plans in place to financially support the following initiatives during the financial year 2025/2026:

- The ongoing provision of family and caregivers accommodation at the Christie Hospital in Manchester.
- We will continue to promote the Family Grants to give financial support where appropriate.
- We will continue to monitor the team at the Basingstoke Hospital on the research programme which aims to analyse patient data to craft a machine learning predictive model for recurrence and survival, to guide clinical decisions and treatment plans.
- The team at the Christie Hospital in Manchester are in very early stage discussions with us regarding a new research project for which funding of £100,000 may be requested.
- We will have discussions with the Christie Hospital in Manchester to continue to monitor and support the prehabilitation study.
- We will keep in touch with all of our patients and caregivers especially when we know that they are going through stressful situations.
- We will continue to closely monitor the Norwegian GNAS research programme, which has now been approved and entered into patient trials.

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Recruitment and appointment of new trustees

Trustees are appointed by the existing trustees. We are delighted that Madeleine Lomas has been appointed a Trustee with effect 23 June 2025.

Organisational structure

In addition to the Trustees we have a group of volunteers who actively undertake the day to day administration of the Facebook group and a further 60 who volunteer as Buddys on the Buddy scheme.

Our people

Pseudomyxoma Survivor relies entirely on the dedication of volunteers to deliver and manage the activities of our charity. We are fortunate to have five active Trustees, each bringing a wealth of skills and experience that will help us grow and thrive in the years ahead. Their commitment and generosity in giving their time to support the charity is invaluable.

We would also like to extend our heartfelt thanks to all of our volunteers this financial year, particularly those who moderate the Patient group and manage the buddies scheme.

A special acknowledgment goes to Mark Ponsford, who has led an online patient discussion forum every week since 2018. This remarkable level of commitment to the charity and to fellow patients is deeply appreciated.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1143642

Principal address

Appletree House
Mill Lane, Ellerton
York
YO42 4PA

Trustees


Mrs S Oliver
Mr T Brill
Mrs C Fletcher
Mrs A C Salisbury
Mrs A B Brook (deceased 2.4.25)
Ms M C Lomas (appointed 23.6.25)

Independent Examiner

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2025

Approved by order of the board of trustees on30 December 2025 and signed on its behalf by:


.....
Mrs A C Salisbury - Trustee

**Independent Examiner's Report to the Trustees of
Pseudomyxoma Survivor**

Independent examiner's report to the trustees of Pseudomyxoma Survivor

I report to the charity trustees on my examination of the accounts of Pseudomyxoma Survivor (the Trust) for the year ended 31 August 2025.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Laura Drew

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Date: *6th January 2026*

Pseudomyxoma Survivor

**Statement of Financial Activities
for the Year Ended 31 August 2025**

| | Notes | Unrestricted funds £ | Restricted funds £ | 2025 Total funds £ | 2024 Total funds £ |
|------------------------------------|-------|----------------------------|--------------------------|-----------------------------|-----------------------------|
| INCOME AND ENDOWMENTS FROM | | | | | |
| Donations and legacies | | 120,001 | 1,895 | 121,896 | 64,216 |
| Investment income | 2 | <u>2,473</u> | <u>-</u> | <u>2,473</u> | <u>-</u> |
| Total | | <u>122,474</u> | <u>1,895</u> | <u>124,369</u> | <u>64,216</u> |
| EXPENDITURE ON | | | | | |
| Raising funds | 3 | 9,648 | - | 9,648 | 9,293 |
| Charitable activities | 4 | | | | |
| Charitable activities | | 19,883 | - | 19,883 | 12,621 |
| Grant making | | 14,655 | 36,325 | 50,980 | 53,513 |
| Support costs | | <u>1,920</u> | <u>-</u> | <u>1,920</u> | <u>1,830</u> |
| Total | | <u>46,106</u> | <u>36,325</u> | <u>82,431</u> | <u>77,257</u> |
| NET INCOME/(EXPENDITURE) | | 76,368 | (34,430) | 41,938 | (13,041) |
| Transfers between funds | 12 | <u>(28,955)</u> | <u>28,955</u> | <u>-</u> | <u>-</u> |
| Net movement in funds | | 47,413 | (5,475) | 41,938 | (13,041) |
| RECONCILIATION OF FUNDS | | | | | |
| Total funds brought forward | | 210,374 | 5,475 | 215,849 | 228,890 |
| TOTAL FUNDS CARRIED FORWARD | | <u><u>257,787</u></u> | <u><u>-</u></u> | <u><u>257,787</u></u> | <u><u>215,849</u></u> |


The notes form part of these financial statements

Pseudomyxoma Survivor

**Balance Sheet
31 August 2025**

| | Notes | Unrestricted funds £ | Restricted funds £ | 2025 Total funds £ | 2024 Total funds £ |
|--|-------|-------------------------|-----------------------|--------------------------|--------------------------|
| CURRENT ASSETS | | | | | |
| Debtors | 10 | 1,172 | - | 1,172 | 1,993 |
| Cash at bank | | 258,535 | - | 258,535 | 217,382 |
| | | <u>259,707</u> | <u>-</u> | <u>259,707</u> | <u>219,375</u> |
| CREDITORS | | | | | |
| Amounts falling due within one year | 11 | (1,920) | - | (1,920) | (3,526) |
| | | <u>257,787</u> | <u>-</u> | <u>257,787</u> | <u>215,849</u> |
| NET CURRENT ASSETS | | | | | |
| | | <u>257,787</u> | <u>-</u> | <u>257,787</u> | <u>215,849</u> |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | | | | |
| | | <u>257,787</u> | <u>-</u> | <u>257,787</u> | <u>215,849</u> |
| NET ASSETS | | | | | |
| | | <u>257,787</u> | <u>-</u> | <u>257,787</u> | <u>215,849</u> |
| FUNDS | | | | | |
| Unrestricted funds | 12 | | | 257,787 | 210,374 |
| Restricted funds | | | | - | 5,475 |
| TOTAL FUNDS | | | | <u>257,787</u> | <u>215,849</u> |

The financial statements were approved by the Board of Trustees and authorised for issue on ...30 December 2025.... and were signed on its behalf by:


.....
Mrs A C Salisbury - Trustee

The notes form part of these financial statements

Pseudomyxoma Survivor

Notes to the Financial Statements for the Year Ended 31 August 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

Income received for services provided is accounted for on an accruals basis.

Cash donations, gifts and legacies are included in full in the income and expenditure account as they are received. Any significant non-cash donations are included in the income and expenditure account at the trustees' estimate of their market value when received. The value of voluntary help is not included in the accounts.

Grants and other funding of a revenue nature are deferred and released to the income and expenditure account over the period to which they relate.

Bank interest is included in the income and expenditure account on an accruals basis.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Directors' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Directors do not consider there to be any material estimates and judgements.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

1. ACCOUNTING POLICIES - continued

Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors, are initially recognised at transaction value and subsequently measured at their settlement value.

2. INVESTMENT INCOME

| | 2025 | 2024 |
|--------------------------|--------------|----------|
| | £ | £ |
| Deposit account interest | 2,473 | - |
| | <u>2,473</u> | <u>-</u> |

3. RAISING FUNDS

Raising donations and legacies

| | 2025 | 2024 |
|---------------------------|--------------|--------------|
| | £ | £ |
| Just Giving | 2,173 | 1,325 |
| Costs of generating funds | 7,475 | 7,968 |
| | <u>9,648</u> | <u>9,293</u> |

4. CHARITABLE ACTIVITIES COSTS

| | Direct Costs £ | Grant funding of activities (see note 5) £ | Support costs (see note 6) £ | Totals £ |
|-----------------------|----------------------|---|---------------------------------------|---------------|
| Charitable activities | 19,883 | - | - | 19,883 |
| Grant making | - | 50,980 | - | 50,980 |
| Support costs | - | - | 1,920 | 1,920 |
| | <u>19,883</u> | <u>50,980</u> | <u>1,920</u> | <u>72,783</u> |

5. GRANTS PAYABLE

| | 2025 | 2024 |
|--------------|---------------|---------------|
| | £ | £ |
| Grant making | 50,980 | 53,513 |
| | <u>50,980</u> | <u>53,513</u> |

The total grants paid to institutions during the year was as follows:

| | 2025 | 2024 |
|--------------|---------------|---------------|
| | £ | £ |
| Grants given | 36,000 | 46,000 |
| | <u>36,000</u> | <u>46,000</u> |

A grant totalling £36,000 was awarded to The Peritoneal Malignancy Institute at Basingstoke Hospital towards research to analyse patient data to craft a Machine Learning predictive model for recurrence and survival, to guide clinical decisions and treatment plans.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

6. SUPPORT COSTS

| | |
|---------------|--|
| | Governance costs £ <u>1,920</u> |
| Support costs | |

Support costs, included in the above, are as follows:

| | 2025 Support costs £ | 2024 Total activities £ |
|-------------------------|-------------------------------|----------------------------------|
| Independent examination | <u>1,920</u> | <u>1,830</u> |

7. TRUSTEES' REMUNERATION AND BENEFITS

There was trustees' remuneration totalling £9,000 (2024 - £8,820) but no other benefits for the year ended 31 August 2025 or other benefits for the year ended 31 August 2024.

The remuneration was received by Mrs S Oliver for their role as the Charity's administrator, after much consideration by the board as to how to fill this role. This was recorded in the Charity's board meeting minutes.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 August 2025 nor for the year ended 31 August 2024.

8. STAFF COSTS

There were no staff costs for the year ended 31 August 2025 nor for the year ended 31 August 2024.

The average number of employees during the year was NIL (2024 - NIL).

No employees received emoluments in excess of £60,000.

9. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

| | Unrestricted funds £ | Restricted funds £ | Total funds £ |
|-----------------------------------|----------------------------|--------------------------|---------------------|
| INCOME AND ENDOWMENTS FROM | | | |
| Donations and legacies | <u>58,741</u> | <u>5,475</u> | <u>64,216</u> |
| EXPENDITURE ON | | | |
| Raising funds | 9,293 | - | 9,293 |
| Charitable activities | | | |
| Charitable activities | 12,621 | - | 12,621 |
| Grant making | 22,513 | 31,000 | 53,513 |
| Support costs | <u>1,830</u> | <u>-</u> | <u>1,830</u> |
| Total | <u>46,257</u> | <u>31,000</u> | <u>77,257</u> |
| NET INCOME/(EXPENDITURE) | 12,484 | (25,525) | (13,041) |

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

| 9. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued | Unrestricted funds £ | Restricted funds £ | Total funds £ | |
|---|----------------------------|-----------------------------|-------------------------------|----------------|
| Transfers between funds | (31,000) | 31,000 | - | |
| Net movement in funds | (18,516) | 5,475 | (13,041) | |
| RECONCILIATION OF FUNDS | | | | |
| Total funds brought forward | 228,890 | - | 228,890 | |
| TOTAL FUNDS CARRIED FORWARD | <u>210,374</u> | <u>5,475</u> | <u>215,849</u> | |
| | | | | |
| 10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | | 2025 | 2024 | |
| | | £ | £ | |
| Other debtors | | 1,025 | 1,846 | |
| Prepayments and accrued income | | 147 | 147 | |
| | | <u>1,172</u> | <u>1,993</u> | |
| | | | | |
| 11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | | 2025 | 2024 | |
| | | £ | £ | |
| Trade creditors | | - | 1,696 | |
| Other creditors | | 1,920 | 1,830 | |
| | | <u>1,920</u> | <u>3,526</u> | |
| | | | | |
| 12. MOVEMENT IN FUNDS | | | | |
| | At 1.9.24 | Net movement in funds | Transfers between funds | At |
| | £ | £ | £ | 31.8.25 |
| | | | | £ |
| Unrestricted funds | | | | |
| General fund | 131,276 | 76,368 | (86,357) | 121,287 |
| Designated fund | 79,098 | - | 57,402 | 136,500 |
| | <u>210,374</u> | <u>76,368</u> | <u>(28,955)</u> | <u>257,787</u> |
| Restricted funds | | | | |
| Research fund | 5,475 | (34,430) | 28,955 | - |
| TOTAL FUNDS | <u>215,849</u> | <u>41,938</u> | <u>-</u> | <u>257,787</u> |

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

12. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 122,474 | (46,106) | 76,368 |
| Restricted funds | | | |
| Research fund | 1,570 | (36,000) | (34,430) |
| Family grants | 325 | (325) | - |
| | <u>1,895</u> | <u>(36,325)</u> | <u>(34,430)</u> |
| TOTAL FUNDS | <u>124,369</u> | <u>(82,431)</u> | <u>41,938</u> |

Comparatives for movement in funds

| | At 1.9.23 £ | Net movement in funds £ | Transfers between funds £ | At 31.8.24 £ |
|---------------------------|----------------|----------------------------------|------------------------------------|--------------------|
| Unrestricted funds | | | | |
| General fund | 111,390 | 12,484 | 7,402 | 131,276 |
| Designated fund | 117,500 | - | (38,402) | 79,098 |
| | <u>228,890</u> | <u>12,484</u> | <u>(31,000)</u> | <u>210,374</u> |
| Restricted funds | | | | |
| Research fund | - | (25,525) | 31,000 | 5,475 |
| | <u>-</u> | <u>(25,525)</u> | <u>31,000</u> | <u>5,475</u> |
| TOTAL FUNDS | <u>228,890</u> | <u>(13,041)</u> | <u>-</u> | <u>215,849</u> |

Comparative net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 58,741 | (46,257) | 12,484 |
| Restricted funds | | | |
| Research fund | 5,475 | (31,000) | (25,525) |
| | <u>64,216</u> | <u>(77,257)</u> | <u>(13,041)</u> |
| TOTAL FUNDS | <u>64,216</u> | <u>(77,257)</u> | <u>(13,041)</u> |

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

| | At 1.9.23 £ | Net movement in funds £ | Transfers between funds £ | At 31.8.25 £ |
|---------------------------|-----------------------|----------------------------------|------------------------------------|-----------------------|
| Unrestricted funds | | | | |
| General fund | 111,390 | 88,852 | (78,955) | 121,287 |
| Designated fund | 117,500 | - | 19,000 | 136,500 |
| | <u>228,890</u> | <u>88,852</u> | <u>(59,955)</u> | <u>257,787</u> |
| Restricted funds | | | | |
| Research fund | - | (59,955) | 59,955 | - |
| | <u>228,890</u> | <u>28,897</u> | <u>-</u> | <u>257,787</u> |
| TOTAL FUNDS | <u><u>228,890</u></u> | <u><u>28,897</u></u> | <u><u>-</u></u> | <u><u>257,787</u></u> |

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 181,215 | (92,363) | 88,852 |
| Restricted funds | | | |
| Research fund | 7,045 | (67,000) | (59,955) |
| Family grants | 325 | (325) | - |
| | <u>7,370</u> | <u>(67,325)</u> | <u>(59,955)</u> |
| TOTAL FUNDS | <u><u>188,585</u></u> | <u><u>(159,688)</u></u> | <u><u>28,897</u></u> |

Restricted funds relate to the provision of research funding.

Transfers between funds

Fund transfers during the year relate to the transfers of previously designated funds to cover actual spending in the year.

The designated fund relates to monies set aside for committed future spending.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 August 2025.

PSEUDOMYXOMASURVIVOR


England & Wales - Charity number 1143642

Accounts

REGISTERED CHARITY NUMBER: 1143642

**Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 August 2024
for
Pseudomyxoma Survivor**

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ



The support network for those affected by pseudomyxoma peritonei, appendix cancers and rare peritoneal malignancies

Registered charity 1143642

PSEUDOMYXOMA SURVIVOR - ANNUAL REPORT TO 31 AUGUST 2024

The trustees present their report with the financial statements of the charity for the year ended 31 August 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OUR OBJECTIVES, AIMS AND ACTIVITIES:

Pseudomyxoma Survivor's main objectives (as set out in the Constitution) are:

- To relieve the sickness, mental and emotional distress of those suffering from pseudomyxoma peritonei (PMP), their families and carers.
- To provide funds to support research into pseudomyxoma peritonei, its causes, treatment and cure and to publish the useful results of such research.
- To promote awareness of pseudomyxoma peritonei.

OUR ACHIEVEMENT AND PERFORMANCE:

In order to **support our patients and their caregivers** we have provided:

- A website providing focussed advice, information and support.
- A private Facebook group which has over 1400 members from across the world. Patients are based in predominantly English-speaking countries with members worldwide.
- Practical as well as emotional support to patients and families through our grant programme and have given financial support to 14 families this year (3 applications were declined). A total of £7400 was paid.
- The ongoing provision of a Buddy Scheme to provide one-to-one support to patients and caregivers around the world.
- Access to a family flat in Manchester, to support the families of those patients being treated at The Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains personalised blankets and information about Pseudomyxoma Survivor. We contributed £15,000 during this financial year.
- Ward toiletries to The Christie and Basingstoke.
- Support to patient days at both the Christie and Basingstoke hospitals

In order to **promote awareness of pseudomyxoma peritonei**, Trustees have:

- Attended the 13th International congress on Peritoneal Surface Malignancies (PSOGI) in Venice in October 2023. The congress is dedicated to improving the treatment and survival of peritoneal metastases. Our Trustee, Tim Brill, presented to the full audience about the work of the charity and the journey of a patient.

| Topic | Feedback | Solution? |
|-------------------------------|---|--|
| Charteristics & Reassurance | "How do I find others like me and I on the right path?" | Patients need reassurance that many others have been on that journey |
| Isolation | "Feeling alone from hospital in England - I feel with surrounded by the medical teams" | Provide clear advice and information to help patients manage their recovery. |
| Complex Medical Descriptions | "I don't understand the terms to describe my diagnostic symptoms (e.g. Pseudomyxoma)" | Simplify language to avoid frightening and confusing already anxious patients |
| Practicalities | "What to take into hospital, how soon can I drive, when can I exercise, how soon can I return to work?" | Patients need lots of information to improve recovery |
| Collaboration & Communication | "I want to collaborate previous collections with other patients and to share the burden of end cases" | Keep supporting patients and encourage patient communities can help ongoing care |

* Feedback from Pseudomyxoma Survivor Facebook Group Page

- Attended various sessions hosted by National Voices, Findacure and data studies
- Attended Cancer52 meetings
- Promoted Rare Disease Day (28th February 2024)
- Published monthly posts on all social media channels regarding the disease
- Supported many competitors and volunteers, by providing merchandise for a wide variety of events
- Provided specialist leaflets for the hospitals to hand out to patients.

We have contributed funds to the following **research programmes** during the year to 31 August 2024:

- £31,000 to the Norwegian GNAS Vaccine Trial at Oslo University [Oslo University GNAS research programme](#).

A peptide vaccine targeting mutated GNAS – a potential novel treatment for pseudomyxoma peritonei

Authors


Kjersti Flatmark, Annette Torgersen, Karianne G. Fleten, Ben Davidson, Hedvig Vidarsdottir Juul, Nadia Mensal, Christin Lund-Andersen, Else Marit Inderberg

Correspondence

kjersti.flatmark@tr-research.no

In Brief

Patients with GNAS-mutated pseudomyxoma peritonei (PMP) have a pre-existing immunity against mutated Gsa. Inhibition of anti-tumor T cells by up-regulation of immune checkpoint molecules result in insufficient immune response. The results suggest exploring peptide vaccination with Gsa peptides in combination with immune checkpoint inhibition as a possible curative treatment for PMP and other GNAS mutated cancers.



We continue to provide pro-bono support of research trials and studies, such as

- Patient physiotherapy for Pseudomyxoma peritonei patients with the University of Liverpool,
- Early diagnostic tools application with the University of Nottingham,
- Assistance with an application towards a dietary study in Australia etc.

Pseudomyxoma Survivor's purpose and its activities contribute to the public benefit through activities to support these objectives.

We are here to help patients understand the treatment options, provide leaflets and online resources that they can trust. We represent the PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness of the disease.

We take pride in the stewardship of our donations, which we demonstrated through this year with our committed registration with the Fundraising Regulator.

Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities.

Charitable activities

Pseudomyxoma is entirely reliant upon donations for our income and due to our very generous supporters we have received £55,504 in donations and other income.

We are indebted to all of our fundraisers and their families and friends for their generosity.

Our Facebook support group goes from strength to strength, and we have continued support for the pseudomyxoma peritonei community on RareConnect, a Eurordis initiative which provides a multi-lingual support platform for rare diseases and on the platform operated by Cancer Research.

We have continued to develop a close working relationship with the teams at the Basingstoke and North Hampshire Hospital and The Christie hospital in Manchester which allows us to better support patients and identify research opportunities.

Once again we were able to retain our status with the Great Non Profits organisation.

FINANCIAL REVIEW

Financial position:

We are extremely pleased that we have total funds of £215,849 at the end of the financial year. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

Pseudomyxoma Survivor's income and expenditure is relatively small and consequently the charity does not have sufficient funds to invest in longer term investments such as stocks and shares.

Reserves policy:

Through prudence in our activities, we are now able to ensure that we have a reserve in future years. We will do this through our plan which ensures the charity has reserves to cover our improved grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward, for 12 months. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community. During the year to 31 August 2024, 12 months' expenditure equated to £77,257 whilst reserves at the period end totalled £215,849 and reserves excluding designated funds totalled £136,751.

We have designated expenditure as at the year ended 31 August 2024 of £79,098 (2023: £117,500) which will be spent in accordance with our charitable objectives, aims and activities which are detailed in the Trustee report. All opportunities will be scrutinised in accordance with our due diligence procedures before any expenditure is committed.

Future plans:

Thanks to our very generous donors, we have plans in place to financially support the following initiatives during the financial year 2024/2025:

- The ongoing provision of family and caregivers accommodation at the Christie Hospital in Manchester.
- The team at Basingstoke Hospital and Southampton University are undertaking a research programme into molecular characterisations of PMP and we will continue financial support of this research.
- We will have discussions with the Christie Hospital in Manchester to continue financially supporting the prehabilitation study.
- We will continue to promote the Family Grants to give financial support where appropriate.
- We will keep in touch with all of our patients and caregivers especially when we know that they are going through stressful situations.
- We will continue to closely monitor the Norwegian GNAS research programme

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2024

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Recruitment and appointment of new trustees

Trustees are appointed by the existing trustees.

Organisational structure

In addition to the Trustees we have a group of volunteers who actively undertake the day to day administration of the Facebook group and a further 60 who volunteer as Buddys on the Buddy scheme.

Our people

Pseudomyxoma Survivor is totally reliant upon volunteers to run and administer the activities of the group. We now have five active Trustees who have a wide range of skills and experience that will enable us to grow and flourish in the future. The Trustees give a huge amount of voluntary time to support the Charity.

Special mention this financial year to all of our volunteers, who help moderate the group and look after the buddies scheme.

The Friends of the charity this year that warrant special mention include the following supporters:

- The Alan Boswell Group, who kindly donated £5000 via an employee nomination scheme.
 - Karen's Big Smiles charity trust who kindly donated £10,000 from their final distribution following the closure of the charity.
 - Rebecca Currie who raised awareness and funds, through her school, in celebration of her amazing Mum.
- There are far too many fundraisers and donors to name individually this year but a very special thank you to all those who donated to a successful 'GoFundme' campaign to raise money for the Norwegian research programme.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1143642

Principal address

9 Ilmington Close
Hatton Park
Warwick
CV35 7TL

Trustees


Mrs S Oliver
Mr T Brill
Mrs C Fletcher
Mrs A C Salisbury
Mrs A B Brook

Independent Examiner

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2024

Approved by order of the board of trustees on 6 January 2025 and signed on its behalf by:


.....
Mrs A C Salisbury - Trustee

**Independent Examiner's Report to the Trustees of
Pseudomyxoma Survivor**

Independent examiner's report to the trustees of Pseudomyxoma Survivor

I report to the charity trustees on my examination of the accounts of Pseudomyxoma Survivor (the Trust) for the year ended 31 August 2024.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Laura Drew

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Date: 30th January 2025

Pseudomyxoma Survivor

Statement of Financial Activities
for the Year Ended 31 August 2024

| | Notes | Unrestricted funds £ | Restricted funds £ | 2024 Total funds £ | 2023 Total funds £ |
|------------------------------------|-------|----------------------------|---------------------------|-----------------------------|-----------------------------|
| INCOME AND ENDOWMENTS FROM | | | | | |
| Donations and legacies | | <u>58,741</u> | <u>5,475</u> | <u>64,216</u> | <u>87,687</u> |
| EXPENDITURE ON | | | | | |
| Raising funds | 2 | 9,293 | - | 9,293 | 6,963 |
| Charitable activities | | | | | |
| Charitable activities | 3 | 12,621 | - | 12,621 | 12,915 |
| Grant making | | 22,513 | 31,000 | 53,513 | 85,088 |
| Support costs | | <u>1,830</u> | <u>-</u> | <u>1,830</u> | <u>1,476</u> |
| Total | | <u>46,257</u> | <u>31,000</u> | <u>77,257</u> | <u>106,442</u> |
| NET INCOME/(EXPENDITURE) | | | | | |
| Transfers between funds | 11 | 12,484 <u>(31,000)</u> | (25,525) <u>31,000</u> | (13,041) <u>-</u> | (18,755) <u>-</u> |
| Net movement in funds | | (18,516) | 5,475 | (13,041) | (18,755) |
| RECONCILIATION OF FUNDS | | | | | |
| Total funds brought forward | | <u>228,890</u> | <u>-</u> | <u>228,890</u> | <u>247,645</u> |
| TOTAL FUNDS CARRIED FORWARD | | <u><u>210,374</u></u> | <u><u>5,475</u></u> | <u><u>215,849</u></u> | <u><u>228,890</u></u> |


The notes form part of these financial statements

Pseudomyxoma Survivor

Balance Sheet
31 August 2024

| | Notes | Unrestricted funds £ | Restricted funds £ | 2024 Total funds £ | 2023 Total funds £ |
|--|-------|-------------------------|-----------------------|--------------------------|--------------------------|
| CURRENT ASSETS | | | | | |
| Debtors | 9 | 1,993 | - | 1,993 | 140 |
| Cash at bank | | <u>211,907</u> | <u>5,475</u> | <u>217,382</u> | <u>230,946</u> |
| | | 213,900 | 5,475 | 219,375 | 231,086 |
| CREDITORS | | | | | |
| Amounts falling due within one year | 10 | (3,526) | - | (3,526) | (2,196) |
| NET CURRENT ASSETS | | <u>210,374</u> | <u>5,475</u> | <u>215,849</u> | <u>228,890</u> |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | | | | |
| | | <u>210,374</u> | <u>5,475</u> | <u>215,849</u> | <u>228,890</u> |
| NET ASSETS | | <u>210,374</u> | <u>5,475</u> | <u>215,849</u> | <u>228,890</u> |
| FUNDS | | | | | |
| | 11 | | | | |
| Unrestricted funds | | | | 210,374 | 228,890 |
| Restricted funds | | | | <u>5,475</u> | - |
| TOTAL FUNDS | | | | <u>215,849</u> | <u>228,890</u> |

The financial statements were approved by the Board of Trustees and authorised for issue on 6 January 2025 and were signed on its behalf by:



.....
Mrs A C Salisbury - Trustee

The notes form part of these financial statements

Pseudomyxoma Survivor

Notes to the Financial Statements for the Year Ended 31 August 2024

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

Income received for services provided is accounted for on an accruals basis.

Cash donations, gifts and legacies are included in full in the income and expenditure account as they are received. Any significant non-cash donations are included in the income and expenditure account at the trustees' estimate of their market value when received. The value of voluntary help is not included in the accounts.

Grants and other funding of a revenue nature are deferred and released to the income and expenditure account over the period to which they relate.

Bank interest is included in the income and expenditure account on an accruals basis.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Directors' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Directors do not consider there to be any material estimates and judgements.

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2024

1. ACCOUNTING POLICIES - continued

Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors, are initially recognised at transaction value and subsequently measured at their settlement value.

2. RAISING FUNDS

Raising donations and legacies

| | 2024 | 2023 |
|---------------------------|--------------|--------------|
| | £ | £ |
| Just Giving | 1,325 | 1,422 |
| Costs of generating funds | <u>7,968</u> | <u>5,541</u> |
| | <u>9,293</u> | <u>6,963</u> |

3. CHARITABLE ACTIVITIES COSTS

| | Direct Costs £ | Grant funding of activities (see note 4) £ | Support costs (see note 5) £ | Totals £ |
|-----------------------|----------------------|---|---------------------------------------|---------------|
| Charitable activities | 12,621 | - | - | 12,621 |
| Grant making | - | 53,513 | - | 53,513 |
| Support costs | - | - | 1,830 | 1,830 |
| | <u>12,621</u> | <u>53,513</u> | <u>1,830</u> | <u>67,964</u> |

4. GRANTS PAYABLE

| | 2024 | 2023 |
|--------------|---------------|---------------|
| | £ | £ |
| Grant making | <u>53,513</u> | <u>85,088</u> |

The total grants paid to institutions during the year was as follows:

| | 2024 | 2023 |
|--------------|---------------|---------------|
| | £ | £ |
| Grants given | <u>46,000</u> | <u>76,000</u> |

A grant totalling £31,000 was awarded in the year to the Norwegian Radium Hospital for use in their Norwegian GNAS research programme.

A further grant in the year was awarded in relation to a flat at The Christie Hospital, further details may be found in the Report of the Trustees.

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2024

5. SUPPORT COSTS

| | |
|---------------|------------------|
| | Governance costs |
| | £ |
| Support costs | <u>1,830</u> |

Support costs, included in the above, are as follows:

| | | |
|-------------------------|---------------|------------------|
| | 2024 | 2023 |
| | Support costs | Total activities |
| | £ | £ |
| Independent examination | <u>1,830</u> | <u>1,560</u> |

6. TRUSTEES' REMUNERATION AND BENEFITS

There was trustees' remuneration totalling £8,820 (2023 - £7,560) but no other benefits for the year ended 31 August 2024 or other benefits for the year ended 31 August 2023.

The remuneration was received by Mrs S Oliver for their role as the Charity's administrator, after much consideration by the board as to how to fill this role. This was recorded in the Charity's board meeting minutes.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 August 2024 nor for the year ended 31 August 2023.

7. STAFF COSTS

There were no staff costs for the year ended 31 August 2024 nor for the year ended 31 August 2023.

The average number of employees during the year was NIL (2023 - NIL).

No employees received emoluments in excess of £60,000.

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

| | Unrestricted funds | Restricted funds | Total funds |
|-----------------------------------|--------------------|------------------|----------------|
| | £ | £ | £ |
| INCOME AND ENDOWMENTS FROM | | | |
| Donations and legacies | <u>59,363</u> | <u>28,324</u> | <u>87,687</u> |
| EXPENDITURE ON | | | |
| Raising funds | 6,963 | - | 6,963 |
| Charitable activities | | | |
| Charitable activities | 12,915 | - | 12,915 |
| Grant making | 30,088 | 55,000 | 85,088 |
| Support costs | <u>1,476</u> | - | <u>1,476</u> |
| Total | <u>51,442</u> | <u>55,000</u> | <u>106,442</u> |
| NET INCOME/(EXPENDITURE) | 7,921 | (26,676) | (18,755) |

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2024

| 8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued | | | | |
|---|-----------------------|------------------------|-------------------------|-----------------------|
| | Unrestricted funds | Restricted funds | Total funds | |
| | £ | £ | £ | |
| Transfers between funds | <u>(26,676)</u> | <u>26,676</u> | - | |
| Net movement in funds | (18,755) | - | (18,755) | |
| RECONCILIATION OF FUNDS | | | | |
| Total funds brought forward | 247,645 | - | 247,645 | |
| TOTAL FUNDS CARRIED FORWARD | <u><u>228,890</u></u> | <u><u>-</u></u> | <u><u>228,890</u></u> | |
| | | | | |
| 9. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | | | | |
| | | 2024 | 2023 | |
| | | £ | £ | |
| Other debtors | | 1,846 | 40 | |
| Prepayments and accrued income | | <u>147</u> | <u>100</u> | |
| | | <u><u>1,993</u></u> | <u><u>140</u></u> | |
| | | | | |
| 10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | | | | |
| | | 2024 | 2023 | |
| | | £ | £ | |
| Trade creditors | | 1,696 | 456 | |
| Other creditors | | <u>1,830</u> | <u>1,740</u> | |
| | | <u><u>3,526</u></u> | <u><u>2,196</u></u> | |
| | | | | |
| 11. MOVEMENT IN FUNDS | | | | |
| | At 1.9.23 | Net movement in funds | Transfers between funds | At 31.8.24 |
| | £ | £ | £ | £ |
| Unrestricted funds | | | | |
| General fund | 111,390 | 12,484 | 7,402 | 131,276 |
| Designated fund | <u>117,500</u> | <u>-</u> | <u>(38,402)</u> | <u>79,098</u> |
| | 228,890 | 12,484 | (31,000) | 210,374 |
| Restricted funds | | | | |
| Research fund | - | (25,525) | 31,000 | 5,475 |
| | <u>-</u> | <u>(25,525)</u> | <u>31,000</u> | <u>5,475</u> |
| TOTAL FUNDS | <u><u>228,890</u></u> | <u><u>(13,041)</u></u> | <u><u>-</u></u> | <u><u>215,849</u></u> |

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2024

11. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 58,741 | (46,257) | 12,484 |
| Restricted funds | | | |
| Research fund | 5,475 | (31,000) | (25,525) |
| | <u> </u> | <u> </u> | <u> </u> |
| TOTAL FUNDS | <u>64,216</u> | <u>(77,257)</u> | <u>(13,041)</u> |

Comparatives for movement in funds

| | At 1.9.22 £ | Net movement in funds £ | Transfers between funds £ | At 31.8.23 £ |
|---------------------------|----------------|----------------------------------|------------------------------------|--------------------|
| Unrestricted funds | | | | |
| General fund | 247,645 | 7,921 | (144,176) | 111,390 |
| Designated fund | <u>-</u> | <u>-</u> | <u>117,500</u> | <u>117,500</u> |
| | 247,645 | 7,921 | (26,676) | 228,890 |
| Restricted funds | | | | |
| Research fund | <u>-</u> | <u>(26,676)</u> | <u>26,676</u> | <u>-</u> |
| TOTAL FUNDS | <u>247,645</u> | <u>(18,755)</u> | <u>-</u> | <u>228,890</u> |

Comparative net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 59,363 | (51,442) | 7,921 |
| Restricted funds | | | |
| Research fund | 23,324 | (50,000) | (26,676) |
| Family grants | <u>5,000</u> | <u>(5,000)</u> | <u>-</u> |
| | <u>28,324</u> | <u>(55,000)</u> | <u>(26,676)</u> |
| TOTAL FUNDS | <u>87,687</u> | <u>(106,442)</u> | <u>(18,755)</u> |

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2024

11. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

| | At 1.9.22 £ | Net movement in funds £ | Transfers between funds £ | At 31.8.24 £ |
|---------------------------|----------------|----------------------------------|------------------------------------|--------------------|
| Unrestricted funds | | | | |
| General fund | 247,645 | 20,405 | (136,774) | 131,276 |
| Designated fund | - | - | 79,098 | 79,098 |
| | 247,645 | 20,405 | (57,676) | 210,374 |
| Restricted funds | | | | |
| Research fund | - | (52,201) | 57,676 | 5,475 |
| TOTAL FUNDS | <u>247,645</u> | <u>(31,796)</u> | <u>-</u> | <u>215,849</u> |

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 118,104 | (97,699) | 20,405 |
| Restricted funds | | | |
| Research fund | 28,799 | (81,000) | (52,201) |
| Family grants | 5,000 | (5,000) | - |
| | 33,799 | (86,000) | (52,201) |
| TOTAL FUNDS | <u>151,903</u> | <u>(183,699)</u> | <u>(31,796)</u> |

Restricted funds relate to the provision of research funding.

Transfers between funds

Fund transfers during the year relate to the transfers of previously designated funds to cover actual spending in the year.

The designated fund relates to monies set aside for committed future spending.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2024**

12. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 August 2024.

PSEUDOMYXOMASURVIVOR

England & Wales - Charity number 1143642

Accounts

REGISTERED CHARITY NUMBER: 1143642

**Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 August 2023
for
Pseudomyxoma Survivor**

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Pseudomyxoma Survivor

**Contents of the Financial Statements
for the Year Ended 31 August 2023**

| | Page |
|--|-------------|
| Report of the Trustees | 1 to 4 |
| Independent Examiner's Report | 5 |
| Statement of Financial Activities | 6 |
| Balance Sheet | 7 |
| Notes to the Financial Statements | 8 to 14 |

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2023

The trustees present their report with the financial statements of the charity for the year ended 31 August 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2023

OBJECTIVES AND ACTIVITIES

Objectives and aims

Pseudomyxoma Survivor's main objectives (as set out in the Constitution) are:

- To relieve the sickness, mental and emotional distress of those suffering from pseudomyxoma peritonei (PMP), their families and carers.
- To provide funds to support research into pseudomyxoma peritonei, its causes, treatment and cure and to publish the useful results of such research.
- To promote awareness of pseudomyxoma peritonei.

Significant activities

Main activities undertaken

The activities that supported the objectives of the Charity during the year were:

- The provision of a website providing advice, information and support.
- The provision of a private Facebook group which has over 1000 members from across the world. Patients are based in predominantly English speaking countries with members worldwide.
- We provided practical as well as emotional support to patients and families through our grant programme and have given financial support to fifteen families this year.
- The ongoing provision of a Buddy Scheme to provide one to one support to patients and caregivers around the world.
- The provision of a £50,000 Grant to the Norwegian GNAS vaccine trial at Oslo University.

In order to support our patients and their caregivers we have

- Provided access to a family flat in Manchester, to support the families of those patients being treated at The Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains personalised blankets and information about Pseudomyxoma Survivor. We contributed £15,000 during this financial year.
- Supported fifteen families with financial grants.
- Given ward toiletries to The Christie and Basingstoke.
- Run a programme of regional meetups for patient and caregivers.
- Contributed £700 towards the cost of individual online physiotherapy sessions for a group of seven patient.

In order to promote awareness of pseudomyxoma peritonei, Trustees have:

- Attended various online sessions hosted by the Small Charities Coalition, National Voices and Findacure
- Attended the Cancer52 meetings online
- Attended relevant EuroPMP meetings
- Promote Rare Disease Day (28th February 2023)
- Presented at the joint global webinar with ACPMP and PALS to promote PMP Awareness Month (August)
- Paid for six NHS staff to undertake a course on how to deliver Hyperthermic intraperitoneal chemotherapy.

As part of our charitable aims and objectives we have contributed funds to the following research programmes during the year to 31 August 2023:

- £11,000 to the Christie Hospital Prehabilitation research project
- £50,000 to the Norwegian GNAS Vaccine Trial at Oslo University Oslo University GNAS research programme.

Pseudomyxoma Survivor's purpose and its activities contribute to the public benefit through activities to support these objectives.

We are here to help patients understand the treatment options, provide leaflets and online resources that they can trust.

We represent the PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness of the disease.

We take pride in the stewardship of our donations which we demonstrated through this year with our committed registration with the Fundraising Regulator.

Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities.

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2023

ACHIEVEMENT AND PERFORMANCE

Charitable activities

Pseudomyxoma is entirely reliant upon donations for our income and due to our very generous supporters we have received £87,687 in donations and other income. We are indebted to all of our fundraisers and their families and friends for their generosity.

Our Facebook support group goes from strength to strength and we have continued support for the pseudomyxoma peritonei community on RareConnect, a Eurordis initiative which provides a multi-lingual support platform for rare diseases.

We have continued to develop a close working relationship with the teams at the Basingstoke and North Hampshire Hospital and The Christie in Manchester which allows us to better support patients and identify research opportunities.

Once again we are able to retain our status with the Great NonProfits organisation.

FINANCIAL REVIEW

Financial position

We are extremely pleased that we have total funds of £228,974 at the end of the financial year. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

Pseudomyxoma Survivor's income and expenditure is relatively small and consequently the charity does not have sufficient funds to invest in longer term investments such as stock and shares.

Reserves policy

Through prudence in our activities, we are now in a position to be able to ensure that we have a reserve in future years. We will do this through our plan which ensures the charity has reserves to cover our improved grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward, for 12 months. With more appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community. During the year to 31 August 2023, 12 months' running costs equated to £15,108, whilst reserves at the period end totalled £228,890 and reserves excluding designated funds totalled £111,390.

We have designated expenditure as at the year ended 31 August 2023 of £117,500 which will be spent in accordance with our charitable objectives, aims and activities which are detailed in the Trustee report. All opportunities will be scrutinised in accordance with our due diligence procedures before any expenditure is committed.

FUTURE PLANS

Thanks to our very generous donors, we have plans in place to financially support the following initiatives during the financial year 2023/2024:

- The ongoing provision of family and caregivers accommodation at the Christie Hospital in Manchester.
- The team at Basingstoke Hospital and Southampton University are undertaking a research programme into molecular characterisations of PMP and we will continue financial support of this research.
- We will have discussions with the Christie Hospital in Manchester to continue financially supporting the prehabilitation study.
- We will continue to promote the Family Grants to give financial support where appropriate.
- We will keep in touch with all of our patients and caregivers especially when we know that they are going through stressful situations.
- We will continue to closely monitor the Norwegian GNAS research programme.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Pseudomyxoma Survivor

**Report of the Trustees
for the Year Ended 31 August 2023**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Recruitment and appointment of new trustees

Trustees are appointed by the existing trustees.

Organisational structure

In addition to the Trustees we have a group of volunteers who actively undertake the day to day administration of the Facebook group and a further 60 who volunteer as Buddys on the Buddy scheme.

Our people

Pseudomyxoma Survivor is totally reliant upon volunteers to run and administer the activities of the group. We now have five active Trustees who have a wide range of skills and experience that will enable us to grow and flourish in the future. The Trustees give a huge amount of voluntary time to support the Charity.

Special mention this financial year to all of our volunteers, who help moderate the group and look after the buddies scheme.

The Friends of the charity this year that warrant special mention include the following supporters:

- The Alan Boswell Group, who kindly donated £5000 via an employee nomination scheme.
 - Karen's Big Smiles charity trust who kindly donated £10,000 from their final distribution following the closure of the charity.
 - Rebecca Currie who raised awareness and funds, through her school, in celebration of her amazing Mum.
- There are far too many fundraisers and donors to name individually this year but a very special thank you to all those who donated to a successful 'GoFundme' campaign to raise money for the Norwegian research programme.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1143642

Principal address

9 Ilmington Close
Hatton Park
Warwick
CV35 7TL


Trustees

Mrs S Oliver
Mr T Brill (appointed 1.1.23)
Mrs C Fletcher
Mrs A C Salisbury
Mrs A B Brook

Independent Examiner

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Approved by order of the board of trustees on 8 December 2023 and signed on its behalf by:


.....
Mrs A C Salisbury - Trustee

**Independent Examiner's Report to the Trustees of
Pseudomyxoma Survivor**

Independent examiner's report to the trustees of Pseudomyxoma Survivor

I report to the charity trustees on my examination of the accounts of Pseudomyxoma Survivor (the Trust) for the year ended 31 August 2023.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Laura Drew

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Date: 11/12/2023

Pseudomyxoma Survivor

**Statement of Financial Activities
for the Year Ended 31 August 2023**

| | Notes | Unrestricted funds £ | Restricted funds £ | 2023 Total funds £ | 2022 Total funds £ |
|------------------------------------|-------|----------------------------|---------------------------|-----------------------------|-----------------------------|
| INCOME AND ENDOWMENTS FROM | | | | | |
| Donations and legacies | | 59,363 | 28,324 | 87,687 | 67,193 |
| EXPENDITURE ON | | | | | |
| Raising funds | 2 | 6,963 | - | 6,963 | 4,128 |
| Charitable activities | | | | | |
| Charitable activities | 3 | 12,915 | - | 12,915 | 10,873 |
| Grant making | | 30,088 | 55,000 | 85,088 | 15,397 |
| Support costs | | 1,476 | - | 1,476 | 1,656 |
| Total | | <u>51,442</u> | <u>55,000</u> | <u>106,442</u> | <u>32,054</u> |
| NET INCOME/(EXPENDITURE) | | | | | |
| Transfers between funds | 11 | 7,921 <u>(26,676)</u> | (26,676) <u>26,676</u> | (18,755) <u>-</u> | 35,139 <u>-</u> |
| Net movement in funds | | (18,755) | - | (18,755) | 35,139 |
| RECONCILIATION OF FUNDS | | | | | |
| Total funds brought forward | | 247,645 | - | 247,645 | 212,506 |
| TOTAL FUNDS CARRIED FORWARD | | <u><u>228,890</u></u> | <u><u>-</u></u> | <u><u>228,890</u></u> | <u><u>247,645</u></u> |


The notes form part of these financial statements

Pseudomyxoma Survivor

Balance Sheet
31 August 2023

| | Notes | Unrestricted funds £ | Restricted funds £ | 2023 Total funds £ | 2022 Total funds £ |
|--|-------|----------------------------|--------------------------|-----------------------------|-----------------------------|
| CURRENT ASSETS | | | | | |
| Debtors | 9 | 140 | - | 140 | 180 |
| Cash at bank | | 230,946 | - | 230,946 | 250,141 |
| | | <u>231,086</u> | - | <u>231,086</u> | <u>250,321</u> |
| CREDITORS | | | | | |
| Amounts falling due within one year | 10 | (2,196) | - | (2,196) | (2,676) |
| | | <u>228,890</u> | - | <u>228,890</u> | <u>247,645</u> |
| NET CURRENT ASSETS | | | | | |
| | | <u>228,890</u> | - | <u>228,890</u> | <u>247,645</u> |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | | | | |
| | | <u>228,890</u> | - | <u>228,890</u> | <u>247,645</u> |
| NET ASSETS | | | | | |
| | | <u>228,890</u> | - | <u>228,890</u> | <u>247,645</u> |
| FUNDS | | | | | |
| Unrestricted funds | 11 | | | <u>228,890</u> | <u>247,645</u> |
| TOTAL FUNDS | | | | | |
| | | | | <u>228,890</u> | <u>247,645</u> |

The financial statements were approved by the Board of Trustees and authorised for issue on 8 December 2023 and were signed on its behalf by:


Mrs A C Salisbury - Trustee

The notes form part of these financial statements

Pseudomyxoma Survivor

Notes to the Financial Statements for the Year Ended 31 August 2023

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

Income received for services provided is accounted for on an accruals basis.

Cash donations, gifts and legacies are included in full in the income and expenditure account as they are received. Any significant non-cash donations are included in the income and expenditure account at the trustees' estimate of their market value when received. The value of voluntary help is not included in the accounts.

Grants and other funding of a revenue nature are deferred and released to the income and expenditure account over the period to which they relate.

Bank interest is included in the income and expenditure account on an accruals basis.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Directors' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Directors do not consider there to be any material estimates and judgements.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

1. ACCOUNTING POLICIES - continued

Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors, are initially recognised at transaction value and subsequently measured at their settlement value.

2. RAISING FUNDS

Raising donations and legacies

| | 2023 | 2022 |
|---------------------------|--------------|--------------|
| | £ | £ |
| Just Giving | 1,422 | 1,418 |
| Costs of generating funds | 5,541 | 2,710 |
| | <u>6,963</u> | <u>4,128</u> |

3. CHARITABLE ACTIVITIES COSTS

| | Direct Costs £ | Grant funding of activities (see note 4) £ | Support costs (see note 5) £ | Totals £ |
|-----------------------|----------------------|---|---------------------------------------|---------------|
| Charitable activities | 12,831 | - | 84 | 12,915 |
| Grant making | - | 85,088 | - | 85,088 |
| Support costs | - | - | 1,476 | 1,476 |
| | <u>12,831</u> | <u>85,088</u> | <u>1,560</u> | <u>99,479</u> |

4. GRANTS PAYABLE

| | 2023 | 2022 |
|--------------|---------------|---------------|
| | £ | £ |
| Grant making | 85,088 | 15,397 |
| | <u>85,088</u> | <u>15,397</u> |

5. SUPPORT COSTS

| | Governance costs £ |
|-----------------------|--------------------------|
| Charitable activities | 84 |
| Support costs | 1,476 |
| | <u>1,560</u> |

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

5. SUPPORT COSTS - continued

Support costs, included in the above, are as follows:

| | Charitable activities £ | Support costs £ | 2023 Total activities £ | 2022 Total activities £ |
|-------------------------|-------------------------------|-----------------------|----------------------------------|----------------------------------|
| Independent examination | 84 | 1,476 | 1,560 | 1,656 |
| | <u>84</u> | <u>1,476</u> | <u>1,560</u> | <u>1,656</u> |

6. TRUSTEES' REMUNERATION AND BENEFITS

There was trustees' remuneration totalling £7,560 (2022 - £8,640) but no other benefits for the year ended 31 August 2023 or other benefits for the year ended 31 August 2022.

The remuneration was received by Mrs S Oliver for their role as the Charity's administrator, after much consideration by the board as to how to fill this role. This was recorded in the Charity's board meeting minutes.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 August 2023 nor for the year ended 31 August 2022.

7. STAFF COSTS

There were no staff costs for the year ended 31 August 2023 nor for the year ended 31 August 2022.

The average number of employees during the year was NIL (2022 - NIL).

No employees received emoluments in excess of £60,000.

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

| | Unrestricted funds £ | Restricted funds £ | Total funds £ |
|-----------------------------------|----------------------------|--------------------------|---------------------|
| INCOME AND ENDOWMENTS FROM | | | |
| Donations and legacies | 67,193 | - | 67,193 |
| | <u>67,193</u> | <u>-</u> | <u>67,193</u> |
| EXPENDITURE ON | | | |
| Raising funds | 4,128 | - | 4,128 |
| Charitable activities | | | |
| Charitable activities | 10,873 | - | 10,873 |
| Grant making | 15,397 | - | 15,397 |
| Support costs | 1,656 | - | 1,656 |
| | <u>32,054</u> | <u>-</u> | <u>32,054</u> |
| Total | <u>32,054</u> | <u>-</u> | <u>32,054</u> |
| NET INCOME | 35,139 | - | 35,139 |
| RECONCILIATION OF FUNDS | | | |
| Total funds brought forward | 212,506 | - | 212,506 |

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2023

| 8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued | | | | |
|--|----------------------------|----------------------------------|------------------------------------|--------------------|
| | Unrestricted funds £ | Restricted funds £ | Total funds £ | |
| TOTAL FUNDS CARRIED FORWARD | <u>247,645</u> | <u>-</u> | <u>247,645</u> | |
| 9. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | | | | |
| | | 2023 £ | 2022 £ | |
| Other debtors | | 40 | - | |
| Prepayments and accrued income | | <u>100</u> | <u>180</u> | |
| | | <u>140</u> | <u>180</u> | |
| 10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | | | | |
| | | 2023 £ | 2022 £ | |
| Trade creditors | | 456 | 1,020 | |
| Other creditors | | <u>1,740</u> | <u>1,656</u> | |
| | | <u>2,196</u> | <u>2,676</u> | |
| 11. MOVEMENT IN FUNDS | | | | |
| | At 1.9.22 £ | Net movement in funds £ | Transfers between funds £ | At 31.8.23 £ |
| Unrestricted funds | | | | |
| General fund | 247,645 | 7,921 | (144,176) | 111,390 |
| Designated fund | <u>-</u> | <u>-</u> | <u>117,500</u> | <u>117,500</u> |
| | 247,645 | 7,921 | (26,676) | 228,890 |
| Restricted funds | | | | |
| Research fund | <u>-</u> | <u>(26,676)</u> | <u>26,676</u> | <u>-</u> |
| TOTAL FUNDS | <u>247,645</u> | <u>(18,755)</u> | <u>-</u> | <u>228,890</u> |

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

11. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 59,363 | (51,442) | 7,921 |
| Restricted funds | | | |
| Research fund | 23,324 | (50,000) | (26,676) |
| Family grants | 5,000 | (5,000) | - |
| | <u>28,324</u> | <u>(55,000)</u> | <u>(26,676)</u> |
| TOTAL FUNDS | <u>87,687</u> | <u>(106,442)</u> | <u>(18,755)</u> |

Comparatives for movement in funds

| | At 1.9.21 £ | Net movement in funds £ | At 31.8.22 £ |
|---------------------------|----------------|----------------------------------|--------------------|
| Unrestricted funds | | | |
| General fund | 212,506 | 35,139 | 247,645 |
| TOTAL FUNDS | <u>212,506</u> | <u>35,139</u> | <u>247,645</u> |

Comparative net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 67,193 | (32,054) | 35,139 |
| TOTAL FUNDS | <u>67,193</u> | <u>(32,054)</u> | <u>35,139</u> |

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

11. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

| | At 1.9.21 £ | Net movement in funds £ | Transfers between funds £ | At 31.8.23 £ |
|---------------------------|-----------------------|----------------------------------|------------------------------------|-----------------------|
| Unrestricted funds | | | | |
| General fund | 212,506 | 43,060 | (144,176) | 111,390 |
| Designated fund | - | - | 117,500 | 117,500 |
| | <u>212,506</u> | <u>43,060</u> | <u>(26,676)</u> | <u>228,890</u> |
| Restricted funds | | | | |
| Research fund | - | (26,676) | 26,676 | - |
| | <u>-</u> | <u>(26,676)</u> | <u>26,676</u> | <u>-</u> |
| TOTAL FUNDS | <u><u>212,506</u></u> | <u><u>16,384</u></u> | <u><u>-</u></u> | <u><u>228,890</u></u> |

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 126,556 | (83,496) | 43,060 |
| Restricted funds | | | |
| Research fund | 23,324 | (50,000) | (26,676) |
| Family grants | 5,000 | (5,000) | - |
| | <u>28,324</u> | <u>(55,000)</u> | <u>(26,676)</u> |
| TOTAL FUNDS | <u><u>154,880</u></u> | <u><u>(138,496)</u></u> | <u><u>16,384</u></u> |

Restricted funds relate to the provision of a research grant to the Norwegian GNAS vaccine trial at Oslo University and grants provided to families in need.

Transfers between funds

The transfer from general funds to restricted funds relate to an allocation to the Research fund which required additional funding in the year.

The designated fund relates to monies set aside for committed future spending.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2023**

12. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 August 2023.

PSEUDOMYXOMASURVIVOR

England & Wales - Charity number 1143642

Accounts

REGISTERED CHARITY NUMBER: 1143642

**Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 August 2022
for
Pseudomyxoma Survivor**

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2022

The trustees present their report with the financial statements of the charity for the year ended 31 August 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Pseudomyxoma Survivor's main objectives (as set out in the Constitution) are:

- To relieve the sickness, mental and emotional distress of those suffering from pseudomyxoma peritonei (PMP), their families and carers.
- To provide funds to support research into pseudomyxoma peritonei, its causes, treatment and cure and to publish the useful results of such research.
- To promote awareness of pseudomyxoma peritonei.

Significant activities

Main activities undertaken

The activities that supported the objectives of the Charity during the year were:

- The provision of a website providing advice, information and support.
- The provision of a private Facebook group which has over 1000 members from across the world. Patients are based in predominantly English speaking countries with members worldwide.
- We provided practical as well as emotional support to patients and families through our grant programme and have given financial support to nine families this year.
- The ongoing provision of a Buddy Scheme to provide one to one support to patients and caregivers around the world.

In order to support our patients and their caregivers:

- We have provided access to a family flat in Manchester, to support the families of those patients being treated at The Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains personalised blankets and information about Pseudomyxoma Survivor.
- Christie Hospital Prehabilitation research project - £11,000 donated in March 2022.
- We have supported eighteen families with financial grants
- Ward toiletries were sent to The Christie and Basingstoke.
- Presented to the 2021 online PSOGI conference
- Commenced a programme of regional meetups for patient and caregivers

In order to promote awareness of pseudomyxoma peritonei, Trustees:

- Attended various online sessions hosted by the Small Charities Coalition, National Voices and Findacure
- Attended the Cancer52 meetings online
- Attended relevant EuroPMP meetings
- Promote Rare Disease Day (28th February 2022)
- Co-ordinated a global approach to PMP Awareness Month (August)

Pseudomyxoma Survivor's purpose and its activities contribute to the public benefit through activities to support these objectives.

We are here to help patients understand the treatment options, provide leaflets and online resources that they can trust.

We represent the PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness of the disease.

We take pride in the stewardship of our donations which we demonstrated through this year with our committed registration with the Fundraising Regulator.

Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities.

Pseudomyxoma Survivor

Report of the Trustees for the Year Ended 31 August 2022

ACHIEVEMENT AND PERFORMANCE

Charitable activities

Pseudomyxoma is entirely reliant upon donations for our income and due to our very generous supporters we have received £67,193 in donations and other income. We are indebted to all of our fundraisers and their families and friends for their generosity.

This has meant that we have been able to consolidate funds to ensure the sustainability of the charity and are now in a position to be planning to commit to research programmes in the future and to have reserves.

Our Facebook support group goes from strength to strength and we have continued support for the pseudomyxoma peritonei community on RareConnect, a Eurordis initiative which provides a multi-lingual support platform for rare diseases.

We have continued to develop a close working relationship with the teams at the Basingstoke and North Hampshire Hospital and The Christie in Manchester which allows us to better support patients and identify research opportunities.

Once again we able to retain our status with the Great NonProfits organisation.

FINANCIAL REVIEW

Financial position

We are extremely pleased that we have total funds of £247,645 at the end of the financial year. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

Pseudomyxoma Survivor's income and expenditure is relatively small and consequently the charity does not have sufficient funds to invest in longer term investments such as stock and shares.

Reserves policy

Through prudence in our activities, we are now in a position to be able to ensure that we have a reserve in future years. We will do this through our plan which ensures the charity has reserves to cover our improved grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward, for 12 months. With more appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community. During the year to 31 August 2022, 12 months' expenditure equated to £32,054, whilst reserves at the period end totalled £247,645.

We have promised funds to other organisations totalling £111,000 as at the year end - 31 August 2022.

- Christie Charitable fund - £15,000 for accommodation as detailed above - awaiting a request for funds.
- Christie Hospital - £11,000 for 2nd stage of the prehabilitation trial, due September 2022.
- Basingstoke Hospital - £35,000 for Molecular study trial. We gave them £15,000 in 2020 and are awaiting a further request for funds as the research develops.
- Norwegian Vaccine Trial - we have promised £50,000 but we haven't agreed a 'contract'/schedule of payment with them yet.

FUTURE PLANS

Thanks to our very generous donors, we have plans in place to financially support the following initiatives during the financial year 2022/2023:

- The ongoing provision of family and caregivers accommodation at the Christie Hospital in Manchester.
 - The team at Basingstoke Hospital and Southampton University are undertaking a research programme into molecular characterisations of PMP and we will continue financial support of this research.
 - We will have discussions with the Christie Hospital in Manchester to continue financially supporting the prehabilitation study.
 - We will continue to promote the Family Grants to give financial support where appropriate.
 - We will keep in touch with all of our patients and caregivers especially when we know that they are going through stressful situations.
-

Pseudomyxoma Survivor

**Report of the Trustees
for the Year Ended 31 August 2022**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Recruitment and appointment of new trustees

Trustees are appointed by the existing trustees.

Organisational structure

In addition to the Trustees we have a group of volunteers who actively undertake the day to day administration of the Facebook group and a further 60 who volunteer as Buddys on the Buddy scheme.

Our people

Pseudomyxoma Survivor is totally reliant upon volunteers to run and administer the activities of the group. We now have five active Trustees who have a wide range of skills and experience that will enable us to grow and flourish in the future. The Trustees give a huge amount of voluntary time to support the Charity.

Special mention this financial year to all of our volunteers, who help moderate the group and look after the buddies scheme.

Friends of the charity this year that warrant special mention include: Emily Arbuthnot, Peritoneal Malignancy Institute, who ran the London Marathon in aid of Pseudomyxoma Survivor, Duncan Fraser who ran the Ironman in Cork. John Crouch and Kay Standing for their constant support.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1143642

Principal address

9 Ilmington Close
Hatton Park
Warwick
CV35 7TL

Trustees

Mrs S Oliver
Mr T Brill (appointed 1.1.23)
Mrs C Fletcher
Mrs A C Salisbury
Mrs A B Brook

Independent Examiner

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Approved by order of the board of trustees on01/06/2023..... and signed on its behalf by:

.....
Mrs A C Salisbury - Trustee

**Independent Examiner's Report to the Trustees of
Pseudomyxoma Survivor**

Independent examiner's report to the trustees of Pseudomyxoma Survivor

I report to the charity trustees on my examination of the accounts of Pseudomyxoma Survivor (the Trust) for the year ended 31 August 2022.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Laura Drew

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Date: 1st June 2023

Pseudomyxoma Survivor

**Statement of Financial Activities
for the Year Ended 31 August 2022**

| | Notes | 2022 Unrestricted fund £ | 2021 Total funds £ |
|------------------------------------|-------|-----------------------------------|--------------------------|
| INCOME AND ENDOWMENTS FROM | | | |
| Donations and legacies | | 67,193 | 73,196 |
| EXPENDITURE ON | | | |
| Raising funds | 2 | 4,128 | 4,544 |
| Charitable activities | 3 | | |
| Charitable activities | | 10,873 | 3,618 |
| Grant making | | 15,397 | 12,358 |
| Support costs | | 1,656 | 1,048 |
| Total | | 32,054 | 21,568 |
| NET INCOME | | 35,139 | 51,628 |
| RECONCILIATION OF FUNDS | | | |
| Total funds brought forward | | 212,506 | 160,878 |
| TOTAL FUNDS CARRIED FORWARD | | 247,645 | 212,506 |


The notes form part of these financial statements

Pseudomyxoma Survivor

**Balance Sheet
31 August 2022**

| | Notes | 2022 Unrestricted fund £ | 2021 Total funds £ |
|--|-------|-----------------------------------|--------------------------|
| CURRENT ASSETS | | | |
| Debtors | 10 | 180 | 150 |
| Cash at bank | | 250,141 | 213,841 |
| | | <u>250,321</u> | <u>213,991</u> |
| CREDITORS | | | |
| Amounts falling due within one year | 11 | (2,676) | (1,485) |
| | | <u>247,645</u> | <u>212,506</u> |
| NET CURRENT ASSETS | | | |
| | | <u>247,645</u> | <u>212,506</u> |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | | |
| | | <u>247,645</u> | <u>212,506</u> |
| NET ASSETS | | | |
| | | <u><u>247,645</u></u> | <u><u>212,506</u></u> |
| FUNDS | | | |
| Unrestricted funds | 12 | 247,645 | 212,506 |
| | | <u>247,645</u> | <u>212,506</u> |
| TOTAL FUNDS | | | |
| | | <u><u>247,645</u></u> | <u><u>212,506</u></u> |

The financial statements were approved by the Board of Trustees and authorised for issue on 01/06/2023 and were signed on its behalf by:


.....
Mrs A C Salisbury - Trustee

The notes form part of these financial statements

Pseudomyxoma Survivor

Notes to the Financial Statements for the Year Ended 31 August 2022

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

Income received for services provided is accounted for on an accruals basis.

Cash donations, gifts and legacies are included in full in the income and expenditure account as they are received. Any significant non-cash donations are included in the income and expenditure account at the trustees' estimate of their market value when received. The value of voluntary help is not included in the accounts.

Grants and other funding of a revenue nature are deferred and released to the income and expenditure account over the period to which they relate.

Bank interest is included in the income and expenditure account on an accruals basis.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 33% on cost

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2022

1. ACCOUNTING POLICIES - continued

Estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Directors' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Directors do not consider there to be any material estimates and judgements.

Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors, are initially recognised at transaction value and subsequently measured at their settlement value.

2. RAISING FUNDS

Raising donations and legacies

| | 2022 | 2021 |
|---------------------------|--------------|--------------|
| | £ | £ |
| Just Giving | 1,418 | 1,373 |
| Costs of generating funds | 2,710 | 3,171 |
| | <u>4,128</u> | <u>4,544</u> |

3. CHARITABLE ACTIVITIES COSTS

| | Direct Costs £ | Grant funding of activities (see note 4) £ | Support costs (see note 5) £ | Totals £ |
|-----------------------|----------------------|---|---------------------------------------|---------------|
| Charitable activities | 10,873 | - | - | 10,873 |
| Grant making | - | 15,397 | - | 15,397 |
| Support costs | - | - | 1,656 | 1,656 |
| | <u>10,873</u> | <u>15,397</u> | <u>1,656</u> | <u>27,926</u> |

4. GRANTS PAYABLE

| | 2022 | 2021 |
|--------------|---------------|---------------|
| | £ | £ |
| Grant making | <u>15,397</u> | <u>12,358</u> |

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2022**

5. SUPPORT COSTS

| | |
|---------------|--|
| | Governance costs £ <u>1,656</u> |
| Support costs | <u>1,656</u> |

Support costs, included in the above, are as follows:

| | 2022 | 2021 |
|----------------------------|------------------|---------------------|
| | Support costs | Total activities |
| | £ | £ |
| Independent examination | 1,656 | 1,020 |
| Accountancy and legal fees | - | 28 |
| | <u>1,656</u> | <u>1,048</u> |

6. TRUSTEES' REMUNERATION AND BENEFITS

There was trustees' remuneration totalling £8,640 but no other benefits for the year ended 31 August 2022, with no trustees' remuneration or other benefits for the year ended 31 August 2021.

The remuneration was received by Mrs S Oliver for their role as the Charity's administrator, after much consideration by the board as to how to fill this role. This was recorded in the Charity's board meeting minutes.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 August 2022 nor for the year ended 31 August 2021.

7. STAFF COSTS

There were no staff costs for the year ended 31 August 2022 nor for the year ended 31 August 2021.

The average number of employees during the year was NIL (2021 - NIL).

No employees received emoluments in excess of £60,000.

8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

| | |
|-----------------------------------|---------------------------|
| | Unrestricted fund £ |
| INCOME AND ENDOWMENTS FROM | |
| Donations and legacies | <u>73,196</u> |
| EXPENDITURE ON | |
| Raising funds | 4,544 |
| Charitable activities | |
| Charitable activities | 3,618 |
| Grant making | 12,358 |
| Support costs | <u>1,048</u> |
| Total | <u>21,568</u> |

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2022

| | | |
|--|------------------------------------|-------------------------------------|
| 8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued | | Unrestricted fund £ |
| | | <u> </u> |
| | NET INCOME | 51,628 |
| | RECONCILIATION OF FUNDS | |
| | Total funds brought forward | 160,878 |
| | | <u> </u> |
| | TOTAL FUNDS CARRIED FORWARD | <u><u>212,506</u></u> |
| 9. TANGIBLE FIXED ASSETS | | Computer equipment £ |
| | | <u> </u> |
| | COST | |
| | At 1 September 2021 | 379 |
| | Disposals | (379) |
| | | <u> </u> |
| | At 31 August 2022 | - |
| | | <u> </u> |
| | DEPRECIATION | |
| | At 1 September 2021 | 379 |
| | Eliminated on disposal | (379) |
| | | <u> </u> |
| | At 31 August 2022 | - |
| | | <u> </u> |
| | NET BOOK VALUE | |
| | At 31 August 2022 | <u> </u> |
| | At 31 August 2021 | <u><u> </u></u> |
| 10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | | |
| | | 2022 2021 |
| | | £ £ |
| | Trade debtors | - 150 |
| | Prepayments and accrued income | 180 - |
| | | <u> </u> <u> </u> |
| | | <u><u>180</u></u> <u><u>150</u></u> |

Pseudomyxoma Survivor

Notes to the Financial Statements - continued
for the Year Ended 31 August 2022

| 11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR | | | |
|---|--------------|--|--------------|
| | 2022 | | 2021 |
| | £ | | £ |
| Trade creditors | 1,020 | | 465 |
| Other creditors | 1,656 | | 1,020 |
| | <u>2,676</u> | | <u>1,485</u> |

| 12. MOVEMENT IN FUNDS | | | |
|------------------------------|----------------|-----------------------|----------------|
| | At 1.9.21 | Net movement in funds | At 31.8.22 |
| | £ | £ | £ |
| Unrestricted funds | | | |
| General fund | 212,506 | 35,139 | 247,645 |
| | <u>212,506</u> | <u>35,139</u> | <u>247,645</u> |
| TOTAL FUNDS | <u>212,506</u> | <u>35,139</u> | <u>247,645</u> |

Net movement in funds, included in the above are as follows:

| | Incoming resources | Resources expended | Movement in funds |
|---------------------------|--------------------|--------------------|-------------------|
| | £ | £ | £ |
| Unrestricted funds | | | |
| General fund | 67,193 | (32,054) | 35,139 |
| | <u>67,193</u> | <u>(32,054)</u> | <u>35,139</u> |
| TOTAL FUNDS | <u>67,193</u> | <u>(32,054)</u> | <u>35,139</u> |

Comparatives for movement in funds

| | At 1.9.20 | Net movement in funds | At 31.8.21 |
|---------------------------|----------------|-----------------------|----------------|
| | £ | £ | £ |
| Unrestricted funds | | | |
| General fund | 160,878 | 51,628 | 212,506 |
| | <u>160,878</u> | <u>51,628</u> | <u>212,506</u> |
| TOTAL FUNDS | <u>160,878</u> | <u>51,628</u> | <u>212,506</u> |

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2022**

12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 73,196 | (21,568) | 51,628 |
| TOTAL FUNDS | <u>73,196</u> | <u>(21,568)</u> | <u>51,628</u> |

A current year 12 months and prior year 12 months combined position is as follows:

| | At 1.9.20 £ | Net movement in funds £ | At 31.8.22 £ |
|---------------------------|----------------|----------------------------------|-----------------|
| Unrestricted funds | | | |
| General fund | 160,878 | 86,767 | 247,645 |
| TOTAL FUNDS | <u>160,878</u> | <u>86,767</u> | <u>247,645</u> |

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 140,389 | (53,622) | 86,767 |
| TOTAL FUNDS | <u>140,389</u> | <u>(53,622)</u> | <u>86,767</u> |

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 August 2022.

PSEUDOMYXOMASURVIVOR

England & Wales - Charity number 1143642

Accounts

REGISTERED CHARITY NUMBER: 1143642

**REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2021
FOR
PSEUDOMYXOMA SURVIVOR**

Harrison Beale & Owen Limited
Chartered Accountants
Highdown House
11 Highdown Road
Leamington Spa
Warwickshire
CV31 1XT

PSEUDOMYXOMA SURVIVOR
CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 August 2021

| | Page |
|--|---------|
| Report of the Trustees | 1 to 4 |
| Independent Examiner's Report | 5 |
| Statement of Financial Activities | 6 |
| Balance Sheet | 7 |
| Notes to the Financial Statements | 8 to 11 |
| Detailed Statement of Financial Activities | 12 |

PSEUDOMYXOMA SURVIVOR

REPORT OF THE TRUSTEES for the year ended 31 August 2021

The trustees present their report with the financial statements of the charity for the year ended 31 August 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Pseudomyxoma Survivor's main objectives (as set out in the Constitution) are:

- To relieve the sickness, mental and emotional distress of those suffering from pseudomyxoma peritonei (PMP), their families and carers,
- To provide funds to support research into pseudomyxoma peritonei, its causes, treatment and cure and to publish the useful results of such research.
- To promote awareness of pseudomyxoma peritonei.

Main activities undertaken

The activities that supported the objectives of the Charity during the year were:

- The provision of a website providing advice, information and support.
- The provision of a private Facebook group which has over 1000 members from across the world. Patients are based in predominantly English speaking countries with members worldwide.
- We provided practical as well as emotional support to patients and families through our grant programme and have given financial support to nine families this year.
- The ongoing provision of a Buddy Scheme to provide one to one support to patients and caregivers around the world.

In order to support our patients and their caregivers:

- We have provided access to a family flat in Manchester, to support the families of those patients being treated at The Christie. The flat is managed by the Christie Charitable Fund on our behalf. Due to the Covid-19 pandemic the referrals were reduced with only 1 family being able to stay for 2 weeks. The funds are being held by The Christie charity to ensure availability as soon as it is required. The flat contains personalised blankets and information about Pseudomyxoma Survivor. £15,000 was paid towards this.
- We have supported nine families with financial grants
- Cards and small gifts were sent to all of the staff who look after PMP patients at Basingstoke hospital, The Christie and The Mater in Dublin in December 2020. Circa 250 staff.
- Ward toiletries were sent to The Christie and Basingstoke.
- We gifted books to those who attended the talk by The Menopause Doctor.
- We provided many online courses/information for patients. Including post-operative physiotherapy for nine patients (which we paid for, provided by Pinc and Steel), meditation, counselling (covering many different subject areas including grief and sense of self), surgical menopause, the pathology of PMP and appendix cancers, Tai Chi and yoga.
-
- We kept up to date with relevant coronavirus legislation and shared updates as necessary.

In order to promote awareness of pseudomyxoma peritonei, Trustees:

- Attended the Christie patient day in April 2021 and spoke at the event
- Attended various online sessions hosted by the Small Charities Coalition and by National Voices
- Attended the Cancer52 meetings online
- Attended relevant EuroPMP meetings
- Promote Rare Disease Day (8th April 2021) and PMP Awareness Month (August)

Pseudomyxoma Survivor's purpose and its activities contribute to the public benefit through activities to support these objectives. We are here to help patients understand the treatment options, provide leaflets and online resources that they can trust. We represent the PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness of the disease.

We take pride in the stewardship of our donations which we demonstrated through this year with our committed registration with the Fundraising Regulator.

PSEUDOMYXOMA SURVIVOR

REPORT OF THE TRUSTEES for the year ended 31 August 2021

Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities.

OUR PEOPLE

Pseudomyxoma Survivor is totally reliant upon volunteers to run and administer the activities of the group. We now have five active Trustees who have a wide range of skills and experience that will enable us to grow and flourish in the future. The Trustees give a huge amount of voluntary time to support the Charity.

Special mention this financial year to all of our volunteers, who help moderate the group and look after the buddies scheme.

Friends of the charity this year that warrant special mention include: Dr Jason Spendelow, Clinical Psychologist, who has also joined us as a medical advisor on our panel, Professor Norman Carr, Pathologist, a current medical advisor for us and Ms Nina Finbow and Mr Nils Blythe who ran a series of after dinner online talks with authors, QC etc including Evan Davies and Griff Rhys Jones.

PSEUDOMYXOMA SURVIVOR

REPORT OF THE TRUSTEES for the year ended 31 August 2021

In addition to the Trustees we have a group of volunteers who actively undertake the day to day administration of the Facebook group and a further 60 who volunteer as Buddys on the Buddy scheme.

ACHIEVEMENT AND PERFORMANCE

The Covid-19 pandemic continued throughout this financial year, which meant that the majority of public fundraising events that would normally be held in the second half of our financial year were cancelled due to severe restrictions on public gatherings.

Pseudomyxoma Survivor is entirely reliant upon donations for our income and due to our very generous supporters we have received £73,197 in donations and other income. We are indebted to all of our fundraisers and their families and friends for their generosity.

This has meant that we have been able to consolidate funds to ensure the sustainability of the charity and are now in a position to be planning to commit to research programmes in the future and to have reserves.

Our Facebook support group goes from strength to strength and we have continued support for the pseudomyxoma peritonei community on RareConnect, a Eurordis initiative which provides a multi-lingual support platform for rare diseases.

We have continued to develop a close working relationship with the teams at the Basingstoke and North Hampshire Hospital and The Christie in Manchester which allows us to better support patients and identify research opportunities.

Once again we were able to retain our status with the Great NonProfits organisation.

FUTURE PLANS

Thanks to our very generous donors, we have plans in place to financially support the following initiatives during the financial year 2021/2022:

- The ongoing provision of family and caregivers accommodation at the Christie Hospital in Manchester.
- The team at Basingstoke Hospital and Southampton University are undertaking a research programme into molecular characterisations of PMP and we will continue financial support of this research.
- We will have discussions with the Christie Hospital in Manchester to continue financially supporting the pre-rehabilitation study.
- We will continue to promote the Family Grants to give financial support where appropriate.
- We will keep in touch with all of our patients and caregivers especially when we know that they are going through stressful situations.

FINANCIAL REVIEW

We are extremely pleased that we have total funds of £212,506 at the end of the financial year. Through prudence in our activities, we are able to ensure that we will have a reserve in future years. We will do this through our plan which ensures the charity always has reserves to cover our improved grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

Pseudomyxoma Survivor's Income and Expenditure is relatively small and consequently the charity does not have sufficient funds to invest in longer term investments such as stocks and shares.

Reserves policy

Through prudence in our activities, we are now in a position to be able to ensure that we have a reserve in future years. We will do this through our plan which ensures the charity has reserves to cover our improved grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward. With more appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

PSEUDOMYXOMA SURVIVOR

**REPORT OF THE TRUSTEES
for the year ended 31 August 2021**

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes an unincorporated charity. Trustees are appointed by the existing trustees.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1143642

Principal address

9 Ilmington Close
Hatton Park
Warwick
Warwickshire
CV35 7TL

Trustees

| | | |
|-------------------|---------------------|----------------------|
| Ms A Brook | Trustee - Secretary | |
| Ms S Oliver | Trustee - Chair | |
| Ms A Salisbury | Trustee – Treasurer | |
| Dr G Morgan | Trustee | Died in June 2021 |
| Mrs C Hancocks | Trustee | Resigned May 2021 |
| Ms Clare Fletcher | Trustee | Appointed April 2021 |
| Ms Alison Allam | Trustee | Appointed May 2021 |

Independent examiner

Mark Ashfield BA FCA
Harrison Beale & Owen Limited
Chartered Accountants
Highdown House
11 Highdown Road
Leamington Spa
Warwickshire
CV31 1XT

Approved by order of the board of trustees onand signed on its behalf by:

.....
Mrs A Salisbury - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
PSEUDOMYXOMA SURVIVOR**

Independent examiner's report to the trustees of Pseudomyxoma Survivor

I report to the charity trustees on my examination of the accounts of the Pseudomyxoma Survivor (the Trust) for the year ended 31 August 2021.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mark Ashfield BA FCA
Harrison Beale & Owen Limited
Highdown House
11 Highdown Road
Leamington Spa
Warwickshire
CV31 1XT

Date:

PSEUDOMYXOMA SURVIVOR

**STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 August 2021**

| | | 2021 | 2020 |
|------------------------------------|-------|-----------------------|----------------|
| | | Unrestricted | Total funds |
| | | fund | |
| | | £ | £ |
| INCOME AND ENDOWMENTS FROM | Notes | | |
| Donations and legacies | | <u>73,197</u> | <u>65,429</u> |
| Total | | 73,197 | 65,429 |
| | | | |
| EXPENDITURE ON | | | |
| Raising funds | 2 | 4,545 | 5,509 |
| Charitable activities | | | |
| Grant making | | 12,358 | 27,808 |
| Charitable activities | | 3,618 | 2,797 |
| Support costs | | <u>1,048</u> | <u>761</u> |
| Total | | 21,569 | 36,875 |
| | | | |
| Other | | <u>-</u> | <u>-</u> |
| Total | | 21,569 | 36,875 |
| | | | |
| NET INCOME | | 51,628 | 28,554 |
| | | | |
| RECONCILIATION OF FUNDS | | | |
| Total funds brought forward | | 160,878 | 132,324 |
| | | | |
| TOTAL FUNDS CARRIED FORWARD | | <u>212,506</u> | <u>160,878</u> |

CONTINUING OPERATIONS

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

PSEUDOMYXOMA SURVIVOR

BALANCE SHEET
At 31 August 2021

| | | 2021 | 2020 |
|--|-------|-----------------------|----------------|
| | | Unrestricted | Total |
| | | fund | funds |
| | | £ | £ |
| CURRENT ASSETS | Notes | | |
| Debtors | 7 | 150 | - |
| Cash at bank and in hand | | <u>213,841</u> | <u>162,401</u> |
| | | 213,991 | 162,401 |
| CURRENT LIABILITIES | 8 | <u>(1,485)</u> | <u>(1,523)</u> |
| NET CURRENT ASSETS | | <u>212,506</u> | <u>160,878</u> |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | <u>212,506</u> | <u>160,878</u> |
| NET ASSETS | | <u>212,506</u> | <u>160,878</u> |
| FUNDS | 9 | | |
| Unrestricted funds | | <u>212,506</u> | <u>160,878</u> |
| TOTAL FUNDS | | <u>212,506</u> | <u>160,878</u> |

The financial statements were approved by the Board of Trustees on and were signed on its behalf by:

.....
Mrs A Salisbury -Trustee

The notes form part of these financial statements

PSEUDOMYXOMA SURVIVOR

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 August 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. RAISING FUNDS

Raising donations and legacies

| | 2021 | 2020 |
|---------------------------|---------------------|--------------|
| | £ | £ |
| Just giving | 1,373 | 1,358 |
| Costs of generating funds | <u>3,172</u> | <u>4,151</u> |
| | <u>4,545</u> | <u>5,509</u> |

PSEUDOMYXOMA SURVIVOR

NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
for the year ended 31 August 2021

3. GRANTS PAYABLE

| | 2021 | 2020 |
|-----------------------|---------------|---------------|
| | £ | £ |
| Grant making | 12,358 | 27,808 |
| Charitable activities | 3,618 | 2,797 |
| Support costs | <u>1,048</u> | <u>761</u> |
| | <u>17,024</u> | <u>31,366</u> |

4. SUPPORT COSTS

| | 2021 | 2020 |
|----------------------------------|--------------|------------|
| | £ | £ |
| Independent examination services | 1,020 | 570 |
| Legal costs | <u>28</u> | <u>191</u> |
| | <u>1,048</u> | <u>761</u> |

5. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 August 2021 nor for the year ended 31 August 2020.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 August 2021 nor for the year ended 31 August 2020.

6. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

| | Unrestricted fund |
|------------------------------------|-------------------|
| | £ |
| INCOME AND ENDOWMENTS FROM | |
| Donations and legacies | <u>65,429</u> |
| Total | 65,429 |
| EXPENDITURE ON | |
| Raising funds | 5,509 |
| Charitable activities | |
| Grant making | 27,808 |
| Charitable activities | 2,797 |
| Support costs | <u>761</u> |
| Total | 36,875 |
| Other | <u>-</u> |
| Total | <u>36,875</u> |
| NET INCOME | 28,554 |
| RECONCILIATION OF FUNDS | |
| Total funds brought forward | <u>132,324</u> |
| TOTAL FUNDS CARRIED FORWARD | <u>160,878</u> |

PSEUDOMYXOMA SURVIVOR

NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
for the year ended 31 August 2021

7. CURRENT ASSETS

| | 2021 | 2020 |
|---------------|-------------------|-----------------|
| | £ | £ |
| Trade debtors | <u>150</u> | - |
| | <u><u>150</u></u> | <u><u>-</u></u> |

8. CURRENT LIABILITIES

| | 2021 | 2020 |
|------------------------------|---------------------|---------------------|
| | £ | £ |
| Trade creditors | 465 | 983 |
| Accruals and deferred income | <u>1,020</u> | <u>540</u> |
| | <u><u>1,485</u></u> | <u><u>1,523</u></u> |

9. MOVEMENT IN FUNDS

| | At 1.9.20 | Net movement in funds | At 31.8.21 |
|---------------------------|-----------------------|-----------------------------|-----------------------|
| | £ | £ | £ |
| Unrestricted funds | | | |
| General fund | 160,878 | 51,628 | 212,506 |
| | <u> </u> | <u> </u> | <u> </u> |
| TOTAL FUNDS | <u><u>160,878</u></u> | <u><u>51,628</u></u> | <u><u>212,506</u></u> |

Net movement in funds, included in the above are as follows:

| | Incoming resources | Resources expended | Movement in funds |
|---------------------------|-----------------------|------------------------|----------------------|
| | £ | £ | £ |
| Unrestricted funds | | | |
| General fund | 73,197 | (21,569) | 51,628 |
| | <u> </u> | <u> </u> | <u> </u> |
| TOTAL FUNDS | <u><u>73,197</u></u> | <u><u>(21,569)</u></u> | <u><u>51,628</u></u> |

PSEUDOMYXOMA SURVIVOR

NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
for the year ended 31 August 2021

9. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

| | At 1.9.19 £ | Net movement in funds £ | At 31.8.20 £ |
|---------------------------|----------------|----------------------------------|-----------------|
| Unrestricted Funds | | | |
| General fund | 132,324 | 28,554 | 160,878 |
| | <hr/> | <hr/> | <hr/> |
| TOTAL FUNDS | <u>132,324</u> | <u>28,554</u> | <u>160,878</u> |

Comparative net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 65,429 | (36,875) | 28,554 |
| | <hr/> | <hr/> | <hr/> |
| TOTAL FUNDS | <u>65,429</u> | <u>(36,875)</u> | <u>28,554</u> |

10. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 August 2021.

PSEUDOMYXOMA SURVIVOR

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
for the year ended 31 August 2021**

| | 2021 £ | 2020 £ |
|---------------------------------------|----------------------|----------------------|
| INCOME AND ENDOWMENTS | | |
| Donations and legacies | | |
| Donations | 67,901 | 46,473 |
| Other Income | <u>5,296</u> | <u>18,956</u> |
| | <u>73,197</u> | <u>65,429</u> |
| Total incoming resources | 73,197 | 65,429 |
| EXPENDITURE | | |
| Raising donations and legacies | | |
| Just giving | 1,373 | 1,358 |
| Costs of generating funds | <u>3,172</u> | <u>4,151</u> |
| | 4,545 | 5,509 |
| Charitable activities | | |
| Postage and stationery | 1,105 | 1,507 |
| Awareness raising | 637 | 19 |
| Bank charges | 43 | 20 |
| Travel & subsistence | 59 | 753 |
| Membership & Subscriptions | 197 | 412 |
| Telephone | 27 | 10 |
| Patient support services | 1,550 | 76 |
| Grants | <u>12,358</u> | <u>27,808</u> |
| | 15,976 | 30,605 |
| Other | | |
| Depreciation of tangible fixed assets | - | - |
| Support costs | | |
| Governance costs | | |
| Auditors' remuneration | 1,020 | 570 |
| Accountancy and legal fees | <u>28</u> | <u>191</u> |
| | <u>1,048</u> | <u>761</u> |
| Total resources expended | 21,569 | 36,875 |
| Net income | <u><u>51,628</u></u> | <u><u>28,554</u></u> |

This page does not form part of the statutory financial statements